Additionally, he helped lead Agios’ transition from an early-stage research company to a late-stage clinical organization with lead assets enasidenib and ivosidenib (now marketed as IDHIFA ® and ...
In the same batch of announcements Ivosidenib (Tibsovo) was also accepted for treating adults with advanced cholangiocarcinoma, a cancer of the bile ducts. Teclistamab (Tecvayli) was accepted as well, ...
Acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) are blood cell cancers that start in the bone marrow. AML is more common and more aggressive than CML. AML is usually treated with ...
It’s a major change of direction for Boston-based Agios, which has been concentrating on the oncology market since its inception in 2008, bringing the Bristol Myers Squibb-partnered Tibsovo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback